A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate the Efficacy and Safety of SHR-1905 in Subjects With Severe Uncontrolled Asthma.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yanfen Wang
- Phone Number: +86 18662172332
- Email: Yanfen.Wang@hengrui.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510163
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged between 18 and 75 years (inclusive)
- Weight ≥ 40 kg
- Meet the diagnostic criteria for asthma and have a medical history of at least 1 year
- Treatment with a total daily dose of either medium or high dose inhaled glucocorticoids (ICS) for at least 6 months before screening, with a stable use for 3 months before randomization
- At least one additional maintenance asthma controller with stable use for at least 3 months before randomization
- At least 2 exacerbations within 12 months before screening
- No birth plan and must agree to take effective contraceptive methods
- Sign informed consent form voluntarily for the trial
Exclusion Criteria:
- Any clinically important pulmonary disease
- Any disease other than asthma that may affect lung function
- Any disease other than asthma related to elevation of eosinophils
- Any immunodeficiency disease
- Any clinically important serious cardiovascular diseases unstable or uncontrolled
- Uncontrolled Hypertension
- Uncontrolled Diabetes Mellitus
- Any clinically important infections within 4 weeks before randomization
- Any major surgery within 3 months before randomized, or any surgical plan during the study, or any treatment that may affect the evaluation of the subjects considered by the investigator
- Any parasitic infections within 6 months before randomization
- Malignancy diagnosed within 5 years before randomization
- Abnormal laboratory tests during screening and baseline
- Positive infectious disease test
- Prolonged QTc interval or other clinical significant abnormal findings in ECG at screening that may cause safety risk to the subject
- Current smoker or smoking cessation for less than 6 months at screening, or smoking history ≥10 pack- years
- Drug or alcohol abuse
- Allergy history to any biologicsl or other agent that investigator think the subject should not participate in the study
- Subjects who are pregnant or breastfeeding, or plan to become pregnant during the study
- Participated in other clinical trials and used investigational drugs containing active ingredients within 4 weeks or 5 half-lives before screening
- Any other circumstance inappropriate for participating in the clinical trial considered by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
subcutaneous ,placebo
|
|
Experimental: Cohort A
dose 1
|
subcutaneous
|
|
Experimental: Cohort B
dose 2
|
subcutaneous
|
|
Experimental: Cohort C
dose 3
|
subcutaneous
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Efficacy:Annual asthma exacerbation rate (AAER)
Time Frame: From randomisation to 48 weeks
|
From randomisation to 48 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes from baseline in Asthma Control questionnaire (ACQ-6) scores
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
Changes from baseline in Asthmatic Quality of Life Questionnaire (AQLQ) scores
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
AAER associated with hospitalization at 48 weeks
Time Frame: From randomisation to 48 weeks
|
From randomisation to 48 weeks
|
|
The proportion of subjects with acute exacerbations of asthma
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
Changes from baseline in weekly reliever use
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
Changes from baseline in weekly mean morning and evening peak expiratory flow (PEF)
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
Changes from baseline in weekly mean number of night time awakenings
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
Time to the first acute asthma exacerbation
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
|
The proportion of subjects with composite endpoint for asthma (CompEx)
Time Frame: Baseline to72 weeks
|
Baseline to72 weeks
|
|
Pharmacokinetics (PK): Serum concentration of SHR-1905
Time Frame: 72 weeks
|
72 weeks
|
|
Changes of fractional exhaled nitric oxide (FeNO) compared with baseline
Time Frame: Baseline to72 weeks
|
Baseline to72 weeks
|
|
Changes from baseline in Asthma Symptom Diary scores
Time Frame: Baseline to 72 weeks
|
Baseline to 72 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHR-1905-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.